{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T03:02:49Z","timestamp":1787022169127,"version":"build-2736575974"},"reference-count":45,"publisher":"Public Library of Science (PLoS)","issue":"3","license":[{"start":{"date-parts":[[2025,3,28]],"date-time":"2025-03-28T00:00:00Z","timestamp":1743120000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004012","name":"Jane ja Aatos Erkon S\u00e4\u00e4ti\u00f6","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004012","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006306","name":"Sigrid Jus\u00e9liuksen S\u00e4\u00e4ti\u00f6","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006306","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005425","name":"Uudenmaan Rahasto","doi-asserted-by":"publisher","award":["-"],"award-info":[{"award-number":["-"]}],"id":[{"id":"10.13039\/501100005425","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005633","name":"Syd\u00e4ntutkimuss\u00e4\u00e4ti\u00f6","doi-asserted-by":"publisher","award":["-"],"award-info":[{"award-number":["-"]}],"id":[{"id":"10.13039\/501100005633","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:p>\n                    Acute myeloid leukemia (AML) is characterized by several recurrent mutations that affect disease biology and phenotype, response to therapy and risk of subsequent relapse. Though tyrosine kinase inhibitors have gained regulatory approval for the treatment of AML, it is unclear whether single drugs targeting a specific genomic alteration will be sufficient to eradicate disease. Fortuitously, kinase\/bromodomain inhibitors allow targeting of downstream transcriptional effectors of oncogenic pathways, allowing impediment of drug resistance at the transcriptional level. Successful development of combinatorial therapeutic strategies to inhibit both upstream oncogenic pathways and their downstream effectors could thus impede the onset of resistant disease. By using a combination of high-throughput cell-based screening assays and structure-based design, we have developed a novel anti-proliferative 3i-compound scaffold with a diverse range of single and dual FLT3\/TAF1(2) activity against AML. Our novel approach to target both FLT3 kinase and TAF1(2) bromodomain efficiently maintained potency against haematological cancers. However, reference compounds and\n                    <jats:italic>in vitro<\/jats:italic>\n                    cell viability and cytotoxicity assays in cancer cell lines demonstrated superior effects of high affinity tyrosine kinase inhibition compared to inhibition of the TAF1 bromodomain. Our results highlight the feasibility of dual tyrosine kinase-bromodomain targeting to overcome disease mechanisms while also revealing the increased efficacy of FLT3-targeted compounds in AML.\n                  <\/jats:p>","DOI":"10.1371\/journal.pone.0320443","type":"journal-article","created":{"date-parts":[[2025,3,28]],"date-time":"2025-03-28T14:21:05Z","timestamp":1743171665000},"page":"e0320443","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":4,"title":["Development and comparison of single FLT3-inhibitors to dual FLT3\/TAF1-inhibitors as an anti-leukemic approach"],"prefix":"10.1371","volume":"20","author":[{"given":"Robert S.","family":"Leigh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bogac L.","family":"Kaynak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heikki","family":"Ruskoaho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9687-8197","authenticated-orcid":true,"given":"Mika J.","family":"V\u00e4lim\u00e4ki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2025,3,28]]},"reference":[{"issue":"10147","key":"pone.0320443.ref001","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/S0140-6736(18)31041-9","article-title":"Acute myeloid leukaemia","volume":"392","author":"NJ Short","year":"2018","journal-title":"Lancet"},{"issue":"4","key":"pone.0320443.ref002","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","article-title":"Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel","volume":"129","author":"H D\u00f6hner","year":"2017","journal-title":"Blood"},{"issue":"2","key":"pone.0320443.ref003","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/s41375-018-0357-9","article-title":"Targeting FLT3 mutations in AML: review of current knowledge and evidence","volume":"33","author":"N Daver","year":"2019","journal-title":"Leukemia"},{"issue":"4","key":"pone.0320443.ref004","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1111\/bjh.15032","article-title":"Advances in targeted therapy for acute myeloid leukaemia","volume":"180","author":"S Kayser","year":"2018","journal-title":"Br J Haematol"},{"issue":"6","key":"pone.0320443.ref005","doi-asserted-by":"crossref","first-page":"e914","DOI":"10.1097\/HS9.0000000000000914","article-title":"An Overview of Targeted Therapies in Acute Myeloid Leukemia","volume":"7","author":"S Turkalj","year":"2023","journal-title":"Hemasphere"},{"key":"pone.0320443.ref006","doi-asserted-by":"crossref","DOI":"10.1177\/2040620719827310","article-title":"Emerging treatment paradigms with FLT3 inhibitors in acute myeloid leukemia","volume":"10","author":"NJ Short","year":"2019","journal-title":"Ther Adv Hematol"},{"issue":"12","key":"pone.0320443.ref007","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1002\/gcc.22750","article-title":"New drugs creating new challenges in acute myeloid leukemia","volume":"58","author":"IS Tiong","year":"2019","journal-title":"Genes Chromosomes Cancer"},{"key":"pone.0320443.ref008","first-page":"3286949","article-title":"The Myc\/Max\/Mxd Network Is a Target of Mutated Flt3 Signaling in Hematopoietic Stem Cells in Flt3-ITD-Induced Myeloproliferative Disease","author":"F Basit","year":"2018","journal-title":"Stem Cells Int"},{"issue":"1","key":"pone.0320443.ref009","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1182\/blood-2006-05-024018","article-title":"Activation mechanisms of STAT5 by oncogenic Flt3-ITD","volume":"110","author":"C Choudhary","year":"2007","journal-title":"Blood"},{"issue":"1","key":"pone.0320443.ref010","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s00277-017-3158-8","article-title":"MYC-dependent downregulation of telomerase by FLT3 inhibitors is required for their therapeutic efficacy on acute myeloid leukemia","volume":"97","author":"X Zhang","year":"2017","journal-title":"Ann Hematol"},{"key":"pone.0320443.ref011","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.1406722111","article-title":"BET and HDAC inhibitors induce similar genes and biological effects and synergize to kill in Myc-induced murine lymphoma.","volume":"111","author":"J Bhadury","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6","key":"pone.0320443.ref012","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/j.cell.2011.08.017","article-title":"BET bromodomain inhibition as a therapeutic strategy to target c-Myc","volume":"146","author":"JE Delmore","year":"2011","journal-title":"Cell"},{"issue":"40","key":"pone.0320443.ref013","doi-asserted-by":"crossref","first-page":"16669","DOI":"10.1073\/pnas.1108190108","article-title":"Targeting MYC dependence in cancer by inhibiting BET bromodomains","volume":"108","author":"JA Mertz","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"7327","key":"pone.0320443.ref014","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1038\/nature09504","article-title":"Selective inhibition of BET bromodomains","volume":"468","author":"P Filippakopoulos","year":"2010","journal-title":"Nature"},{"issue":"7586","key":"pone.0320443.ref015","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1038\/nature16508","article-title":"Response and resistance to BET bromodomain inhibitors in triple-negative breast cancer","volume":"529","author":"S Shu","year":"2016","journal-title":"Nature"},{"issue":"10","key":"pone.0320443.ref016","doi-asserted-by":"crossref","first-page":"2824","DOI":"10.1002\/ijc.33047","article-title":"Cotargeting BET proteins overcomes resistance arising from PI3K\/mTOR blockade-induced protumorigenic senescence in colorectal cancer","volume":"147","author":"H-S Lee","year":"2020","journal-title":"Int J Cancer"},{"issue":"10","key":"pone.0320443.ref017","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1158\/1535-7163.MCT-14-0258","article-title":"BET protein antagonist JQ1 is synergistically lethal with FLT3 tyrosine kinase inhibitor (TKI) and overcomes resistance to FLT3-TKI in AML cells expressing FLT-ITD","volume":"13","author":"W Fiskus","year":"2014","journal-title":"Mol Cancer Ther"},{"issue":"4","key":"pone.0320443.ref018","first-page":"1022","article-title":"A novel combination regimen of BET and FLT3 inhibition for FLT3-ITD acute myeloid leukemia","volume":"106","author":"L Lee","year":"2021","journal-title":"Haematologica"},{"issue":"3","key":"pone.0320443.ref019","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1038\/nrc.2016.148","article-title":"A chemical probe toolbox for dissecting the cancer epigenome","volume":"17","author":"J Shortt","year":"2017","journal-title":"Nat Rev Cancer"},{"issue":"20","key":"pone.0320443.ref020","doi-asserted-by":"crossref","first-page":"9301","DOI":"10.1021\/acs.jmedchem.8b01225","article-title":"GNE-371, a Potent and Selective Chemical Probe for the Second Bromodomains of Human Transcription-Initiation-Factor TFIID Subunit 1 and Transcription-Initiation-Factor TFIID Subunit 1-like","volume":"61","author":"S Wang","year":"2018","journal-title":"J Med Chem"},{"issue":"7","key":"pone.0320443.ref021","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1038\/nchembio.2080","article-title":"Mapping the chemical chromatin reactivation landscape identifies BRD4-TAF1 cross-talk","volume":"12","author":"S Sdelci","year":"2016","journal-title":"Nat Chem Biol"},{"issue":"10","key":"pone.0320443.ref022","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1021\/acsmedchemlett.9b00243","article-title":"Dual Inhibition of TAF1 and BET Bromodomains from the BI-2536 Kinase Inhibitor Scaffold","volume":"10","author":"D Remillard","year":"2019","journal-title":"ACS Med Chem Lett"},{"issue":"5","key":"pone.0320443.ref023","doi-asserted-by":"crossref","first-page":"4182","DOI":"10.1021\/acs.jmedchem.1c01999","article-title":"Discovery of Dual TAF1-ATR Inhibitors and Ligand-Induced Structural Changes of the TAF1 Tandem Bromodomain","volume":"65","author":"RM Karim","year":"2022","journal-title":"J Med Chem"},{"issue":"9","key":"pone.0320443.ref024","doi-asserted-by":"crossref","first-page":"4002","DOI":"10.1021\/acs.jmedchem.7b00306","article-title":"Benzoisoquinolinediones as Potent and Selective Inhibitors of BRPF2 and TAF1\/TAF1L Bromodomains","volume":"60","author":"L Bouch\u00e9","year":"2017","journal-title":"J Med Chem"},{"issue":"5","key":"pone.0320443.ref025","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1038\/nrd4286","article-title":"Targeting bromodomains: epigenetic readers of lysine acetylation","volume":"13","author":"P Filippakopoulos","year":"2014","journal-title":"Nat Rev Drug Discov"},{"issue":"5","key":"pone.0320443.ref026","doi-asserted-by":"crossref","first-page":"166689","DOI":"10.1016\/j.bbadis.2023.166689","article-title":"TAF1 bromodomain inhibition as a candidate epigenetic driver of congenital heart disease","author":"RS Leigh","year":"2023","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"issue":"6416","key":"pone.0320443.ref027","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1038\/362179a0","article-title":"The p250 subunit of native TATA box-binding factor TFIID is the cell-cycle regulatory protein CCG1","volume":"362","author":"K Hisatake","year":"1993","journal-title":"Nature"},{"issue":"12","key":"pone.0320443.ref028","doi-asserted-by":"crossref","first-page":"5332","DOI":"10.1128\/MCB.24.12.5332-5339.2004","article-title":"Activation of a DNA damage checkpoint response in a TAF1-defective cell line","volume":"24","author":"AM Buchmann","year":"2004","journal-title":"Mol Cell Biol"},{"key":"pone.0320443.ref029","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.bbrc.2023.04.100","article-title":"Targeting TAF1 with BAY-299 induces antitumor immunity in triple-negative breast cancer","volume":"665","author":"S Zhang","year":"2023","journal-title":"Biochem Biophys Res Commun"},{"issue":"12","key":"pone.0320443.ref030","doi-asserted-by":"crossref","first-page":"5307","DOI":"10.21037\/tcr-21-2295","article-title":"TAF1 inhibitor Bay-299 induces cell death in acute myeloid leukemia","volume":"10","author":"L Zhou","year":"2021","journal-title":"Transl Cancer Res"},{"issue":"17","key":"pone.0320443.ref031","doi-asserted-by":"crossref","first-page":"3261","DOI":"10.1002\/cncr.30745","article-title":"Somatic mutation profiles of clear cell endometrial tumors revealed by whole exome and targeted gene sequencing","volume":"123","author":"M Le Gallo","year":"2017","journal-title":"Cancer"},{"issue":"1","key":"pone.0320443.ref032","first-page":"1","article-title":"TAF1 plays a critical role in AML1-ETO driven leukemogenesis","volume":"10","author":"Y Xu","year":"2019","journal-title":"Nat Commun"},{"issue":"6","key":"pone.0320443.ref033","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1016\/S1097-2765(04)00123-6","article-title":"Phosphorylation on Thr-55 by TAF1 mediates degradation of p53: a role for TAF1 in cell G1 progression","volume":"13","author":"H-H Li","year":"2004","journal-title":"Mol Cell"},{"issue":"3","key":"pone.0320443.ref034","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/j.molcel.2007.09.006","article-title":"An acetylation switch in p53 mediates holo-TFIID recruitment","volume":"28","author":"AG Li","year":"2007","journal-title":"Mol Cell"},{"issue":"11","key":"pone.0320443.ref035","doi-asserted-by":"crossref","first-page":"5391","DOI":"10.1021\/acs.jmedchem.6b00264","article-title":"Diving into the Water: Inducible Binding Conformations for BRD4, TAF1(2), BRD9, and CECR2 Bromodomains","volume":"59","author":"TD Crawford","year":"2016","journal-title":"J Med Chem"},{"issue":"4","key":"pone.0320443.ref036","doi-asserted-by":"crossref","first-page":"e0121177","DOI":"10.1371\/journal.pone.0121177","article-title":"Crystal structure of the FLT3 kinase domain bound to the inhibitor Quizartinib (AC220)","volume":"10","author":"JA Zorn","year":"2015","journal-title":"PLoS One"},{"issue":"17","key":"pone.0320443.ref037","doi-asserted-by":"crossref","first-page":"8284","DOI":"10.1021\/acs.jmedchem.9b01086","article-title":"Synthesis, identification, and structure-activity relationship analysis of GATA4 and NKX2-5 protein-protein interaction modulators","volume":"62","author":"M Jumppanen","year":"2019","journal-title":"J Med Chem"},{"issue":"12","key":"pone.0320443.ref038","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1158\/2159-8290.CD-13-0350","article-title":"Individualized systems medicine strategy to tailor treatments for patients with chemorefractory acute myeloid leukemia","volume":"3","author":"T Pemovska","year":"2013","journal-title":"Cancer Discov"},{"issue":"1","key":"pone.0320443.ref039","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1177\/2211068215618869","article-title":"Precision Cancer Medicine in the Acoustic Dispensing Era: Ex Vivo Primary Cell Drug Sensitivity Testing","volume":"21","author":"E Kulesskiy","year":"2016","journal-title":"J Lab Autom"},{"issue":"12","key":"pone.0320443.ref040","doi-asserted-by":"crossref","first-page":"e0146021","DOI":"10.1371\/journal.pone.0146021","article-title":"Dose-Response Analysis Using R","volume":"10","author":"C Ritz","year":"2015","journal-title":"PLoS One"},{"issue":"1","key":"pone.0320443.ref041","first-page":"1","article-title":"Targeting bromodomain-containing proteins: research advances of drug discovery","volume":"4","author":"Z Pan","year":"2023","journal-title":"Mol Biomed"},{"issue":"22","key":"pone.0320443.ref042","doi-asserted-by":"crossref","first-page":"9393","DOI":"10.1021\/jm300915b","article-title":"Progress in the development and application of small molecule inhibitors of bromodomain-acetyl-lysine interactions","volume":"55","author":"DS Hewings","year":"2012","journal-title":"J Med Chem"},{"issue":"14","key":"pone.0320443.ref043","doi-asserted-by":"crossref","first-page":"2984","DOI":"10.1182\/blood-2009-05-222034","article-title":"AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML)","volume":"114","author":"PP Zarrinkar","year":"2009","journal-title":"Blood"},{"issue":"5","key":"pone.0320443.ref044","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1007\/s10637-017-0470-z","article-title":"Gilteritinib, a FLT3\/AXL inhibitor, shows antileukemic activity in mouse models of FLT3 mutated acute myeloid leukemia","volume":"35","author":"M Mori","year":"2017","journal-title":"Invest New Drugs"},{"issue":"1","key":"pone.0320443.ref045","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1038\/s41594-024-01384-6","article-title":"Resistance of estrogen receptor function to BET bromodomain inhibition is mediated by transcriptional coactivator cooperativity","volume":"32","author":"S Zhang","year":"2024","journal-title":"Nat Struct Mol Biol"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0320443","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,28]],"date-time":"2025-03-28T14:22:21Z","timestamp":1743171741000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0320443"}},"subtitle":[],"editor":[{"given":"Francesco","family":"Bertolini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2025,3,28]]},"references-count":45,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,3,28]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0320443","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,28]]}}}